Pronethalol (hydrochloride)

Pronethalol ((±) -Pronethalo) is a non-selective β-adrenergic antagonist. Pronethalol is a potent inhibitor of Sox2 expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias, and limits the cerebral arteriovenous malformation (AVMs) [1][2].

Product Specifications

CAS Number

[51-02-5]

Product Name Alternative

(±) -Pronethalo (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/pronethalol-hydrochloride.html

Solubility

10 mM in DMSO

Smiles

OC(CNC(C)C)C1=CC=C2C=CC=CC2=C1.Cl

Molecular Formula

C15H20ClNO

Molecular Weight

265.78

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Jiayi Yao, et al. Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations. J Clin Invest. 2019 Jun 24;129 (8) :3121-3133.|[2]Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71 (4) :503-508.|[3]Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71 (4) :503-8.